Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
In patients with esophageal cancer, treatment with curative intent can be given to medically
fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone
or in combination. Surgery in combination with chemotherapy is another option. For patients
who are not medically fit for surgery or with unresectable invasion in adjacent structures
the only alternative with curative intent is, with current knowledge, definitive
chemoradiotherapy. In the current study the investigators aim to improve prognosis for
patients not suitable for surgery. Patients receive treatment with conventional
chemoradiotherapy (oxaliplatin, fluorouracil and radiotherapy) with the addition of a more
recently developed drug, an antibody called cetuximab.